Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib

Ponatinib is a novel multi-tyrosine kinase inhibitor (TKI) with potent inhibitory activity against refractory chronic myeloid leukemia (CML). Despite its high clinical efficacy, ponatinib induces various adverse events due to its multi-target characteristic. However, renal complications associated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Arai, Hiroyuki, Yamamoto, Shinya, Matsubara, Takeshi, Miyake, Takafumi, Tochio, Akira, Mii, Akiko, Shimizu, Akira, Minamiguchi, Sachiko, Muso, Eri, Yanagita, Motoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569927/
https://www.ncbi.nlm.nih.gov/pubmed/36642524
http://dx.doi.org/10.2169/internalmedicine.1283-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569927/
https://www.ncbi.nlm.nih.gov/pubmed/36642524
http://dx.doi.org/10.2169/internalmedicine.1283-22

Ejemplares similares